NorthWest Biotherapeutics Inc (NWBO)

[abeta]

to bring Optune to China.

and signing our collaboration agreement with Zai Lab to bring Optune to China.

In the fourth quarter, there were 13 presentations on Tumor Treating Fields at ASTRO, 55 presentations on Tumor Treating Fields at the EANO and more than 70 presentations on Tumor Treating Fields at SNO.

Looking forward, we believe there is significant opportunity for further growth in our GBM business across geographies. Our teams continue to focus on driving adoption through physician education, clinical research and well permitted direct-to-patient outreach. We believe there are many more patients who can benefit from Optune than are currently on therapy.

Net loss for the quarter was $15.6 million or $0.17 per share.

It seems like that script volume number has been a little volatile. So maybe any color on how we should be thinking about script volumes?

But, as you know, we do not guide, so start there.

Number two, not withstanding that fact, we believe that we have significant opportunity to grow the GBM business in the U.S.A. and in the other markets in which we participate and in markets where we don't participate. That said, it's -- because we have a relatively small indication in GBM and by that I mean relatively small incident and as I've said to many investors, you can't take the incidents and divide by 52 weeks in order to draw a straight line. It is more of what I've always called (inaudible)

https://finance.yahoo.com/news/edited-transcript-nvcr-earnings-conference-170949019.html